Precision Genomic Medicine
Intersect on FHIR™ integrates precision genomic medicine directly into the clinical record and care workflow — surfacing genetic insights at the point of care, connecting specialists across the network, and building toward full molecular tumor board integration on HL7 CodeX standards.
The Problem
Genetic test results live in the genomics lab or genetic counselor's system — disconnected from the EHR, invisible to the PCP managing the patient's other conditions.
When genomic findings do reach the ordering provider, they arrive as PDF attachments or faxes — unstructured, unsearchable, and unable to trigger clinical decision support.
Hereditary cardiovascular conditions affect all populations equally — but genetic testing and counseling remain concentrated in academic centers, leaving rural and underserved patients undiagnosed.
Molecular tumor boards depend on structured genomic data exchange between oncologists, pathologists, and genetic counselors — but most health systems lack the interoperability infrastructure to support them efficiently.
Intersect on FHIR™ treats genomic data as a first-class citizen of the clinical record. GenomicStudy, MolecularSequence, and DiagnosticReport are native FHIR R6 resources — not attachments, not workarounds.
Genetic findings flow into the longitudinal patient record automatically. They inform clinical decision support at the point of prescribing. They are visible to every provider in the network — from the academic specialist to the community PCP who referred the patient.
And as we build toward molecular tumor board integration, we are doing it on the standards being written today by the HL7 CodeX GenomicX workgroup — ensuring what we build will interoperate with any system that follows the same standards.
🧬 FHIR R6 Genomic Resources · NativeClinical Panels
Each panel is a fully realized clinical view — surfacing genetic variants, test results, and clinical recommendations in the context of the patient's complete longitudinal record.
Identifies genetic variants affecting drug metabolism — CYP450 enzymes, drug transporter genes, and pharmacodynamic targets — surfaced at the point of prescribing.
BRCA1, BRCA2, and related hereditary cancer syndrome variants with clinical significance classification and cascade testing workflow support.
MLH1, MSH2, MSH6, PMS2, and EPCAM mismatch repair gene variants associated with Lynch Syndrome and hereditary colorectal cancer risk.
Familial hypercholesterolemia, hypertrophic cardiomyopathy, dilated cardiomyopathy, and related inherited cardiovascular conditions — addressing the 1 in 250 Americans at hereditary risk.
Long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and related inherited arrhythmia syndromes.
Each panel view draws from and contributes to the patient's complete FHIR record — medications, conditions, observations, family history, and encounter history all visible in context.
Pharmacogenomic findings inform drug selection and dosing alerts in the CPOE workflow — the genomic context reaches the prescriber at the moment it matters most.
A genetic test ordered by the academic specialist is visible to the community PCP, the care coordinator, and the patient — in the same platform, in real time.
Genetic counseling visit summaries and result notifications reach patients through the mobile application — supporting informed decision-making and care plan adherence.
The platform's FHIR-native genomic architecture supports the addition of new panels as clinical need and health system priorities evolve — without re-engineering the underlying data model.
Standards Leadership
Intersect Healthcare Systems holds invited membership in the HL7 CodeX FHIR Accelerator — not open enrollment, but a selective community of organizations actively shaping the future of healthcare interoperability. Our participation in the GenomicX domain means we implement genomic data standards from the inside out.
As an active workgroup participant, Intersect contributes to the CodeX GenomicX standards for molecular tumor board data exchange and pathogen genomics interoperability — not just implementing them after the fact.
Our team includes Master of Health Informatics and PharmD credentialed specialists working directly with molecular tumor board program managers — bridging the gap between standards development and clinical reality.
Health systems adopting Intersect on FHIR™ for genomics will be on the same standards framework as every other CodeX implementer — ensuring their genomic data can flow to any compliant system, today and as the ecosystem evolves.
Clinical validation partners working with Intersect on the molecular tumor board workflow will have indirect input into the CodeX standards through our workgroup participation — shaping how genomic data flows across health systems nationally.
Molecular Tumor Board · Roadmap
The molecular tumor board workflow is the capability that transforms Intersect on FHIR™ from a genomics-aware platform into an indispensable tool for academic oncology programs. We are building it on CodeX GenomicX standards — and seeking a clinical validation partner to build it with us.
Oncologist submits a patient case to the tumor board directly from the Intersect clinical record — with genomic variants, pathology findings, and treatment history pre-populated from FHIR resources.
Tumor board members — oncologist, pathologist, genetic counselor, radiologist — review structured genomic data in a shared view built to CodeX GenomicX standards.
Board recommendations are documented as structured FHIR resources — not free text — enabling downstream clinical decision support and longitudinal tracking.
Recommendations flow directly into the patient's longitudinal FHIR record — visible to every provider in the network, informing subsequent prescribing and care decisions.
Five clinical genetic testing panels are built and live in the platform today — providing the genomic data foundation the tumor board workflow will build upon.
Molecular tumor boards are increasingly standard of care in academic oncology — but the data infrastructure to run them efficiently is not. Most boards rely on slide presentations, manual data entry, and unstructured notes. Intersect changes that.
The tumor board workflow will implement the HL7 CodeX GenomicX mCODE (minimal Common Oncology Data Elements) framework — ensuring the structured data we generate is interoperable with any other CodeX-compliant system in the health system's ecosystem.
We are actively seeking a genomics-forward health system to co-develop the molecular tumor board workflow — helping shape the implementation in exchange for early access and direct influence on how the CodeX standards are applied in practice.
Technical Foundation
Every genomic data element in Intersect on FHIR™ is stored and exchanged as a standard FHIR R6 resource — not a PDF, not a proprietary schema, not an attachment. This is what makes true interoperability possible.
Intersect on FHIR™ is pre-commercial and actively seeking its first health system partner for clinical validation. If your organization has a genomics initiative and is ready to help shape the future of precision medicine interoperability, we want to talk.
See how Intersect on FHIR™ brings precision genomic medicine into everyday clinical care.
Request a Demo